Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents
AssigneeNovartis AG
InventorsPeter Houghton, Peter Traxler
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of imatinib of the following formula or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a cancer that expresses breast cancer resistant protein (BCRP) in a human subject in need of such a treatment.
Claims12
1-12. (canceled)
A method for the treatment or inhibition of a cancer expressing breast cancer resistance protein (BCRP) comprising administering imatinib of the formula I
- or a pharmaceutically acceptable salt thereof.
A method for the treatment of a cancer over-expressing breast cancer resistance protein (BCRP) comprising administering imatinib of formula I or a pharmaceutically acceptable salt thereof.
A method to prevent or reverse resistance to an anticancer agent of a cancer that expresses BCRP in a human subject having said cancer comprising administering imatinib of formula I or a pharmaceutically acceptable salt thereof.
A method to improve the absorption of an orally-administered anticancer agent comprising administering imatinib of formula I or a pharmaceutically acceptable salt thereof.
A method to improve the absorption of an orally-administered anticancer agent by inhibiting BCRP in a patient having a cancer comprising administering imatinib of formula I or a pharmaceutically acceptable salt thereof.
A method of treating a cancer that expresses BCRP in a human subject, which comprises administering a therapeutically effective amount of an anticancer agent and an effective BCRP-inhibiting amount of imatinib or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.